Page last updated: 2024-11-05

troglitazone and Arthropathies

troglitazone has been researched along with Arthropathies in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research Excerpts

ExcerptRelevanceReference
" Whereas high dosage of full agonists may expose RA patients to cardiovascular adverse effects, the proof of concept that PPAR agonists have therapeutical relevance to OA may benefit from an epidemiological follow-up of joint lesions in diabetic or hyperlipidemic patients treated for long periods of time with glitazones or fibrates."2.44[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists]. ( Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jouzeau, JY1
Moulin, D1
Koufany, M1
Sebillaud, S1
Bianchi, A1
Netter, P1

Reviews

1 review available for troglitazone and Arthropathies

ArticleYear
[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Journal de la Societe de biologie, 2008, Volume: 202, Issue:4

    Topics: Animals; Arthritis, Rheumatoid; Chromans; Dimerization; Extracellular Matrix; Humans; Hypoglycemic A

2008